id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-6016-0010,FDA,FDA-2017-E-6016,Certificate Extending Patent Term re PARSABIV,Other,Certificate Extending Patent Term,2020-08-03T04:00:00Z,2020,8,2020-08-03T04:00:00Z,,2020-08-03T22:16:11Z,,0,0,09000064847d1071
FDA-2017-E-6016-0009,FDA,FDA-2017-E-6016,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-09-17T04:00:00Z,2019,9,2019-09-17T04:00:00Z,,2019-09-17T13:22:24Z,,0,0,0900006483f86b3e
FDA-2017-E-6016-0006,FDA,FDA-2017-E-6016,"Determination of Regulatory Review Period for Purposes of Patent
Extension; PARSABIV",Notice,Determinations,2018-12-31T05:00:00Z,2018,12,2018-12-31T05:00:00Z,2019-02-27T04:59:59Z,2019-01-09T02:01:46Z,2018-28221,0,0,09000064839d2140
FDA-2017-E-6016-0005,FDA,FDA-2017-E-6016,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T17:44:43Z,,0,0,09000064839c04e4
FDA-2017-E-6016-0004,FDA,FDA-2017-E-6016,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T15:30:34Z,,0,0,090000648378b79e
FDA-2017-E-6016-0003,FDA,FDA-2017-E-6016,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-10-17T04:00:00Z,2017,10,2017-10-17T04:00:00Z,,2017-10-17T20:13:28Z,,0,0,0900006482bd61b5
FDA-2017-E-6016-0002,FDA,FDA-2017-E-6016,Letter from U.S. Patent and Trademark Office,Other,Application,2017-10-04T04:00:00Z,2017,10,2017-10-04T04:00:00Z,,2017-10-04T12:38:39Z,,0,0,0900006482b9ad96
FDA-2017-E-6016-0001,FDA,FDA-2017-E-6016,Patent Extension Application from McDermott Will & Emerly LLP (on behalf of KAI Pharmaceuticals Inc),Other,Application,2017-10-04T04:00:00Z,2017,10,2017-10-04T04:00:00Z,,2017-10-04T12:32:24Z,,0,0,0900006482b9ad3f